LeonaBio, Inc.

DB:6AI Stock Report

Market Cap: €21.1m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

LeonaBio Management

Management criteria checks 2/4

LeonaBio's CEO is Mark Litton, appointed in Oct 2021, has a tenure of 4.25 years. total yearly compensation is $3.18M, comprised of 19.7% salary and 80.3% bonuses, including company stock and options. directly owns 1.09% of the company’s shares, worth €228.95K. The average tenure of the management team and the board of directors is 3 years and 4.1 years respectively.

Key information

Mark Litton

Chief executive officer

US$3.2m

Total compensation

CEO salary percentage19.68%
CEO tenure4.3yrs
CEO ownership1.1%
Management average tenure3yrs
Board average tenure4.1yrs

Recent management updates

No updates

Recent updates

No updates

CEO Compensation Analysis

How has Mark Litton's remuneration changed compared to LeonaBio's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$38m

Jun 30 2025n/an/a

-US$60m

Mar 31 2025n/an/a

-US$80m

Dec 31 2024US$3mUS$625k

-US$97m

Sep 30 2024n/an/a

-US$109m

Jun 30 2024n/an/a

-US$113m

Mar 31 2024n/an/a

-US$116m

Dec 31 2023US$2mUS$585k

-US$118m

Sep 30 2023n/an/a

-US$121m

Jun 30 2023n/an/a

-US$108m

Mar 31 2023n/an/a

-US$102m

Dec 31 2022US$4mUS$543k

-US$96m

Sep 30 2022n/an/a

-US$82m

Jun 30 2022n/an/a

-US$77m

Mar 31 2022n/an/a

-US$67m

Dec 31 2021US$3mUS$450k

-US$55m

Sep 30 2021n/an/a

-US$46m

Jun 30 2021n/an/a

-US$39m

Mar 31 2021n/an/a

-US$27m

Dec 31 2020n/an/a

-US$20m

Sep 30 2020n/an/a

-US$13m

Jun 30 2020n/an/a

-US$6m

Mar 31 2020n/an/a

-US$6m

Dec 31 2019US$204kUS$12k

-US$5m

Compensation vs Market: Mark's total compensation ($USD3.18M) is above average for companies of similar size in the German market ($USD389.70K).

Compensation vs Earnings: Mark's compensation has increased whilst the company is unprofitable.

CEO

Mark Litton (57 yo)

4.3yrs
Tenure
US$3,175,011
Compensation

Dr. Mark J. Litton, Ph D., MBA, serves as Director at Lumen Bioscience, Inc. since October 2020. He served as Chief Operating Officer of LeonaBio, Inc. (formerly known as Athira Pharma, Inc.) since July 20...

Leadership Team

NamePositionTenureCompensationOwnership
Mark Litton
President4.3yrsUS$3.18m1.09%
€ 228.9k
Kevin Church
Chief Scientific Officer3yrsUS$1.34m0.52%
€ 110.6k
Mark Worthington
General Counsel4.6yrsUS$1.34m0.35%
€ 74.8k
Robert Renninger
Chief Financial Officer1.3yrsno data0.33%
€ 68.8k
Julie Rathbun
Head of Investor Relationsno datano datano data
Javier San Martin
Chief Medical Officer1.8yrsno data0.26%
€ 54.5k
3.0yrs
Average Tenure
57yo
Average Age

Experienced Management: 6AI's management team is considered experienced (3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Mark Litton
President4.3yrsUS$3.18m1.09%
€ 228.9k
John Fluke
Independent Director11.1yrsUS$90.90k0.37%
€ 77.5k
Grant Pickering
Independent Director4yrsUS$93.66k0.065%
€ 13.8k
Kelly Romano
Independent Chairwoman of the Board5.1yrsUS$123.65k0.20%
€ 43.2k
Joseph Edelman
Independent Director5.7yrsUS$87.40k0%
€ 0
Hans Moebius
Member of Scientific Advisory Board3.6yrsUS$1.29mno data
Marwan Sabbagh
Member of Scientific Advisory Board3.6yrsno datano data
Barbara Kosacz
Independent Director4.8yrsUS$97.40k0%
€ 0
Michael A. Panzara
Independent Director3.8yrsUS$90.39k0%
€ 0
James Johnson
Independent Director5.4yrsUS$104.90k0.013%
€ 2.7k
John Olichney
Member of Scientific Advisory Board3.6yrsno datano data
Anton Porsteinsson
Member of Scientific Advisory Board3.6yrsno datano data
4.1yrs
Average Tenure
64.5yo
Average Age

Experienced Board: 6AI's board of directors are considered experienced (4.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/22 06:23
End of Day Share Price 2026/01/13 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

LeonaBio, Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Esther Lannie HongBerenberg
Eric SchmidtCantor Fitzgerald & Co.
Jason ButlerCitizens JMP Securities, LLC